Cytoskeletal control of lung blood vessel biology in ARDS
Official title: Cytoskeletal Regulation of Lung Endothelial Pathobiology in ARDS
Funded at University of Florida · NIH-11417270 · Data updated 2026-11-12
A program at a major university is exploring how the cell skeleton in lung blood vessels drives ARDS, with a focus on how leakage and inflammation occur and how this might lead to better therapies.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | September 20, 2016 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $2,141,888 |
| NIH project number | 5P01HL126609-10 |
| Project ID | NIH-11417270 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with ARDS or at risk of severe respiratory failure, including those with COVID-19–related ARDS, and individuals with African ancestry who may have specific genetic insights.
✕Less likely to help
Patients without ARDS or related lung vascular conditions may not directly benefit from this research.
What this research studies
This project aims to understand how the internal skeleton of lung endothelial cells regulates barrier function in ARDS and during ventilator stress. Researchers will study molecular and genetic factors that control vascular permeability and repair, and how these processes contribute to organ failure in ARDS and COVID-19 contexts. The work is translational, connecting basic biology to potential treatments that could reduce lung leakage and inflammation. Four integrated projects will examine target genes, SNPs, CpG sites, and the role of reactive oxygen species in cytoskeletal remodeling to identify new therapeutic opportunities.
Why it matters
Potential benefit: Potentially guiding new therapies to reduce lung leakage and inflammation in ARDS, which could improve survival and organ function.
How similar studies have gone: Previous studies have linked endothelial cytoskeletal dynamics to vascular leak and lung injury, supporting potential for meaningful advances with this approach.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Garcia, Joe G. N. — University of Florida
- Study coordinator: Garcia, Joe G. N.
Related research
Other NIH-funded projects on the same topics.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Lipid-gene Profiles in Septic ARDS
A Mayo Clinic team is studying how dysfunctional HDL in sepsis relates to different ARDS patient outcomes, aiming to find features that could guide better treatment.
-
Improving blood vessel repair after pediatric ARDS
Aims to better repair the lungs of children who have ARDS by delivering targeted therapy to lung blood vessels using tiny nanoparticles.
-
NOX4 links to ARDS risk and progression
Aims to understand how NOX4-driven cell damage may make some adults with ARDS worse off and how this could lead to earlier, targeted care.
-
Leading causes of death in alcoholic ARDS patients using clinical data
This project uses big clinical data and AI to find the main factors that cause death in adults with ARDS who have alcohol use issues, aiming to improve understanding and care.
-
Targeting aging-related blood vessel injury to prevent ARDS in older lungs
Aims to find ways to protect lung blood vessels in older adults to prevent dangerous lung swelling (ARDS).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.